Tyme Technologies (TYME) is touting updated survival results from its P2 open-label study of SM-88 "in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred After/on First Line Chemotherapy". TYME favorably contrast the study's current median overall survival of 6.4 months with the historic OS for this patient population of around 2 months. I note, however, that an inclusion requirement for the trial is "life expectancy >3 months, in the judgment of the investigator." Also note that only 38 of 49 patients were included included in the analysis on a per-protocol basis.
From a PR: "Based on these results, TYME plans to initiate a randomized pivotal trial for use of SM-88 in patients with pancreatic cancer in Q3’2019." And from an ESMO poster: "920 mg/day dose has been selected for further evaluation in anticipated future SM-88 pancreatic pivotal registrational trials."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.